Dogwood Therapeutics, Inc.
DWTX- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001818844
No open-market purchases or sales by Dogwood Therapeutics, Inc. insiders were filed in the last 90 days; 15 institutions reported holding it in 13F filings for Q2 2026, worth $6.16M in total; no superinvestor holds it.
13F holders, Q2 2025
Institutional positions in Dogwood Therapeutics, Inc. as of Jun 30, 2025. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 10
- −3 vs. Q1 2025
- Shares held
- 43.2K
- −38.8K (−47.3%) vs. Q1 2025
- Total value
- $207.5K
- −$202.2K (−49.4%) vs. Q1 2025
- New holders
- 1
- 2 more added
- Sold out
- 4
- 3 more reduced
Compare with Q1 2025: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting DWTX on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 15 | $6.16M |
| Q1 2026 | 13 | $7.64M |
| Q4 2025 | 10 | $292.0K |
| Q3 2025 | 12 | $299.5K |
| Q2 2025 | 10 | $207.5K |
| Q1 2025 | 13 | $409.8K |
| Q4 2024 | 10 | $76.5K |
| Q3 2024 | 24 | $180.3K |
| Q2 2024 | 24 | $212.0K |
| Q1 2024 | 20 | $324.9K |
| Q4 2023 | 20 | $493.4K |
| Q3 2023 | 23 | $766.3K |
| Q2 2023 | 24 | $1.08M |
| Q1 2023 | 23 | $307.1K |
| Q4 2022 | 27 | $307.7K |
| Q3 2022 | 25 | $485.7K |
| Q2 2022 | 17 | $4.80M |
| Q1 2022 | 15 | $4.91M |
| Q4 2021 | 16 | $4.85M |
| Q3 2021 | 13 | $5.30M |
| Q2 2021 | 14 | $5.58M |
| Q1 2021 | 14 | $5.06M |
Institutions, Q2 2025
Shares, value and share of portfolio for each institution holding Dogwood Therapeutics, Inc.; share changes are against Q1 2025.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Morgan Stanley | 17,450 | $83.2K | 0.00% | +16,850+2,808.3% | Added |
| Geode Capital Management, LLC | 12,823 | $61.9K | 0.00% | −1,586−11.0% | Reduced |
| Vanguard Group Inc | 11,782 | $56.9K | 0.00% | 00.0% | Unchanged |
| Tower Research Capital LLC (TRC) | 792 | $3.78K | 0.00% | −258−24.6% | Reduced |
| SBI Securities Co., Ltd. | 153 | $730 | 0.00% | −35−18.6% | Reduced |
| Activest Wealth Management | 120 | $572 | 0.00% | 00.0% | Unchanged |
| BlackRock, Inc. | 30 | $143 | 0.00% | 00.0% | Unchanged |
| Raymond James Financial Inc | 24 | $114 | 0.00% | +24 | New |
| Bank of America Corp | 17 | $81 | 0.00% | +7+70.0% | Added |
| Group One Trading, L.P. | 9 | $43 | 0.00% | 00.0% | Unchanged |
| UBS Group AG | 0 | $0 | 0.00% | −29,818−100.0% | Sold out |
| FNY Investment Advisers, LLC | 0 | $0 | 0.00% | −12,500−100.0% | Sold out |
| HRT Financial LP | 0 | $0 | 0.00% | −11,228−100.0% | Sold out |
| FMR LLC | 0 | $0 | 0.00% | −225−100.0% | Sold out |